Your browser doesn't support javascript.
loading
Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study.
Guedon, Alexis F; Ricard, Laure; Laurent, Charlotte; De Moreuil, Claire; Urbanski, Geoffrey; Deriaz, Sophie; Gerotziafas, Grigorios; Elalamy, Ismail; Audemard, Alexandra; Chasset, Francois; Alamowitch, Sonia; Sellam, Jérémie; Boffa, Jean Jacques; Cohen, Ariel; Wahl, Clémentine; Abisror, Noemie; Maillot, François; Fain, Olivier; Mekinian, Arsène.
Affiliation
  • Guedon AF; Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
  • Ricard L; Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
  • Laurent C; Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
  • De Moreuil C; Service de Médecine Interne, CHRU de Brest, Brest, France.
  • Urbanski G; Service de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire d'Angers, Angers, France.
  • Deriaz S; Service de Médecine Interne, CHRU et université de Tours, Tours, France.
  • Gerotziafas G; Service de Hémostase et Hématologie Biologique, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
  • Elalamy I; Service de Hémostase et Hématologie Biologique, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
  • Audemard A; Service de Médecine Interne, CHRU et université de Tours, Tours, France.
  • Chasset F; Service de Dermatologie et Vénérologie, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
  • Alamowitch S; Service des Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpétrière, AP-HP, Centre de Recherche de Saint Antoine, INSERM, UMRS 938, Sorbonne Université Paris, Paris, France.
  • Sellam J; Service de Rhumatologie, CRSA INSERM, UMRS 938, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France.
  • Boffa JJ; Service de Néphrologie, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
  • Cohen A; Service de Cardiologie, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France.
  • Wahl C; Sorbonne Université, Service d'hématologie biologique, AP-HP, Hôpital Saint-Antoine, Paris, France.
  • Abisror N; Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
  • Maillot F; Service de Médecine Interne, CHRU et université de Tours, Tours, France.
  • Fain O; Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France.
  • Mekinian A; Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France arsene.mekinian@aphp.fr.
RMD Open ; 9(1)2023 03.
Article in En | MEDLINE | ID: mdl-36894193
ABSTRACT

INTRODUCTION:

Antiphospholipid syndrome (APS) is an autoimmune disease characterised by thrombosis (arterial, venous or small vessel) or obstetrical events and persistent antiphospholipid antibodies (aPL), according to the Sydney classification criteria. Many studies have performed cluster analyses among patients with primary APS and associated autoimmune disease, but none has focused solely on primary APS. We aimed to perform a cluster analysis among patients with primary APS and asymptomatic aPL carriers without any autoimmune disease, to assess prognostic value.

METHODS:

In this multicentre French cohort study, we included all patients with persistent APS antibodies (Sydney criteria) measured between January 2012 and January 2019. We excluded all patients with systemic lupus erythematosus or other systemic autoimmune diseases. We performed hierarchical cluster analysis on the factor analysis of mixed data coordinates results with baseline patient characteristics to generate clusters.

RESULTS:

We identified four clusters cluster 1, comprising 'asymptomatic aPL carriers', with low risk of events during follow-up; cluster 2, the 'male thrombotic phenotype', with older patients and more venous thromboembolic events; cluster 3, the 'female obstetrical phenotype', with obstetrical and thrombotic events; and cluster 4, 'high-risk APS', which included younger patients with more frequent triple positivity, antinuclear antibodies, non-criteria manifestations and arterial events. Regarding survival analyses, asymptomatic aPL carriers relapsed less frequently than the others, but no other differences in terms of relapse rates or deaths were found between clusters.

CONCLUSIONS:

We identified four clusters among patients with primary APS, one of which was 'high-risk APS'. Clustering-based treatment strategies should be explored in future prospective studies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Thrombosis / Antiphospholipid Syndrome / Lupus Erythematosus, Systemic Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: RMD Open Year: 2023 Document type: Article Affiliation country: Francia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Thrombosis / Antiphospholipid Syndrome / Lupus Erythematosus, Systemic Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: RMD Open Year: 2023 Document type: Article Affiliation country: Francia